NAD+: A Cell's Redox Currency and Aging's Ticker

The short version

NAD+ stands for Nicotinamide Adenine Dinucleotide. It is not a peptide and not a drug — it is a small molecule that every living cell requires to convert food into energy. Think of it as a rechargeable electron carrier: in its oxidized form (NAD+) it accepts electrons from metabolic reactions; in its reduced form (NADH) it delivers them to the machinery that makes ATP, the cell's fuel ^[4].

Beyond energy, NAD+ is a consumed substrate for a class of enzymes — sirtuins, PARPs, and CD38 — that govern DNA repair, stress responses, and inflammatory signaling. These enzymes use NAD+ up when they work, so the size of the NAD+ pool influences how well they function. Tissue NAD+ declines with age, and that decline has made NAD+ a subject of intensive longevity research ^[4].

The honest position: raising blood NAD+ through precursors like NMN or NR is well-established in human trials. Whether that translates to meaningful clinical benefits — longer healthspan, disease prevention — remains genuinely uncertain. The most current review of the human evidence, published in Nature Metabolism in 2025, concluded that human trial data show limited efficacy and that tissue-specific NAD+ dynamics remain poorly characterized ^[1]. This page summarizes what the studies actually show — it does not recommend any product or dose.

What it is

Nicotinamide Adenine Dinucleotide is a dinucleotide — two nucleotides (nicotinamide mononucleotide and adenosine monophosphate) joined by two bridging phosphate groups. The nicotinamide ring is the working end: it gains or loses a hydride ion, toggling between the oxidized NAD+ and reduced NADH forms. Molecular formula C21H27N7O14P2.

A critical distinction runs through this whole field: NAD+ itself is not what you take orally. Cells cannot easily transport the intact dinucleotide across their membranes. What oral supplements provide are precursors — molecules that cells convert into NAD+ through biosynthetic pathways. The main precursors studied in humans are:

• NMN (Nicotinamide Mononucleotide) — a direct metabolic intermediate one step upstream of NAD+.
• NR (Nicotinamide Riboside) — a nucleoside precursor that cells convert to NMN and then to NAD+.
• Nicotinamide — the simplest niacin-based precursor, effective but may inhibit certain sirtuins at high tissue concentrations.

Keeping precursors distinct from NAD+ itself is not pedantry — the regulatory, pharmacokinetic, and mechanistic stories diverge depending on which form is being discussed ^[1][4].

How it works

NAD+ plays two biological roles simultaneously, and both become relevant to aging:

The redox role. In the mitochondrion, NAD+ accepts electrons from glycolysis and the TCA cycle as NADH, and NADH donates those electrons to Complex I of the electron transport chain, driving the proton gradient that synthesizes ATP. The NAD+/NADH ratio is a direct readout of the cell's energetic state, and the mitochondrial NAD+ pool is essential for aerobic energy production.

The signaling role. NAD+ is also consumed — broken down — by three families of signaling enzymes:

• Sirtuins (SIRT1-SIRT7): NAD+-dependent deacylases that regulate gene expression, mitochondrial biogenesis, DNA repair and stress responses. They require NAD+ as a co-substrate, not just a cofactor — meaning they actually consume it.
• PARPs (poly(ADP-ribose) polymerases): particularly PARP1, activated by DNA strand breaks; it consumes large amounts of NAD+ under genotoxic stress, potentially depleting the pool ^[4].
• CD38 / CD157: ectoenzymes that degrade NAD+ as part of calcium signaling and immune function. Crucially, CD38 activity rises with age, and a landmark 2016 study in mice showed that CD38 knockout mice are protected against the age-related fall in tissue NAD+ — they maintained SIRT3 activity, better mitochondrial function, and healthier metabolic profiles into old age ^[6]. This makes CD38 the strongest mechanistic explanation for why NAD+ declines as we age.

The rate-limiting step in the main salvage pathway is the enzyme NAMPT (nicotinamide phosphoribosyltransferase), which regenerates NMN from nicotinamide. NAMPT activity is a constraint on how much NAD+ the cell can produce from precursors ^[4].

What the research shows

Blood NAD+ elevation — the consistent signal. Multiple human trials have now shown that oral NMN and NR raise blood NAD+ reliably and dose-dependently. In a multicenter, double-blind, placebo-controlled RCT in middle-aged adults, oral NMN at 300–900 mg/day for 60 days dose-dependently raised blood NAD+ at days 30 and 60 (p≤0.001 vs. placebo across all NMN groups). The 600 mg/day arm was identified as optimal; the trial also reported improved walking distance and quality-of-life scores, with no safety issues at any dose ^[2]. In a separate RCT, NR at 100–1000 mg/day for 8 weeks dose-dependently raised whole-blood NAD+ by 22%, 51%, and 142% at the three dose levels in healthy overweight adults, with no flushing and no significant adverse-event differences from placebo ^[5]. The message from both trials is consistent: oral precursors raise blood NAD+ substantially and safely at the doses studied.

Metabolic signaling — a human finding. Beyond blood levels, 10 weeks of oral NMN (250 mg/day) improved muscle insulin sensitivity in prediabetic, postmenopausal women assessed by hyperinsulinemic-euglycemic clamp — a rigorous metabolic measurement. Investigators found evidence of remodeled insulin signaling in muscle tissue. Body composition and HbA1c did not change significantly ^[3]. This is one of the cleaner translational signals in the human literature: a mechanism (NAD+ → sirtuin-mediated metabolic regulation → insulin sensitivity) with a human endpoint.

CD38 and the age-related mechanism. The CD38 knockout study in mice put a named culprit on NAD+ decline: CD38 rises with age (partly driven by age-related inflammation), actively degrades the NAD+ pool, and the resulting NAD+ depletion impairs SIRT3, which in turn impairs mitochondrial function. Preventing CD38 from rising preserved NAD+ and mitochondrial health into old age in that model ^[6]. This has made CD38 inhibition an active research target — a more upstream approach than simply replenishing precursors.

A 2025 mechanistic finding in heart failure. A 2025 study using human myocardium and a murine model of heart failure with preserved ejection fraction (HFpEF) identified a specific mechanism for NAD+ therapy in that condition: NAD+ repletion restored activity of the ketogenic enzyme HMGCS2 via deacetylation, increased fatty acid oxidation, and rescued cardiac function. When HMGCS2 was knocked down in cardiomyocytes, NAD+ therapy could no longer rescue HFpEF — confirming the pathway is HMGCS2-dependent ^[7]. This kind of mechanism-specific finding is notable because it points toward tissue-targeted applications rather than general NAD+ boosting.

The 2025 synthesis: what the human evidence actually shows. A 2025 narrative review in Nature Metabolism assessed the entire human clinical evidence base on NAD+ precursor supplementation in aging. Its conclusions are worth quoting closely, because they represent the most current authoritative synthesis: human trials have shown limited efficacy, age-related NAD+ decline has been consistently observed in only a limited number of human studies, and the body of data on tissue-specific NAD+ dynamics remains sparse. The review underscores the need for more clinical studies of systemic and tissue-specific NAD+ metabolism rather than reliance on rodent extrapolation ^[1]. That is not the headline you will see in supplement marketing — but it is the position of the peer-reviewed record as of 2025.

Reported effects, cautions & safety

Several dimensions of caution are grounded in the published literature:

On oral absorption. Oral NAD+ itself is poorly taken up by cells intact; most experts consider precursors (NMN, NR) the rational oral approach ^[1][4]. Some products sold as "NAD+" capsules may be largely ineffective as NAD+ delivery vehicles; precursor supplements are the form with actual human trial data.

On IV NAD+ therapy. Infused NAD+ is rapidly cleared from plasma, and IV NAD+ wellness therapy is marketed aggressively while resting on minimal controlled evidence. Infusions can cause chest or abdominal discomfort, flushing, and nausea if administered too quickly. Compounded injectable NAD+ carries contamination risk — the FDA has issued a Class I recall of a compounded NAD+ injection for elevated bacterial endotoxin levels. This site does not advise on IV use.

On NMN's regulatory status. The FDA has taken the position that NMN may be excluded from the dietary-supplement definition because it was investigated as a drug before it was marketed as a supplement — a challenge that has created marketplace uncertainty and may affect product availability ^[1].

On the cancer question. A theoretical concern is that boosting NAD+ could fuel the metabolism of existing cancers, since NAD+ supports proliferating cells; NAD+ in oncology has dual, context-dependent roles — pro-tumor in some settings, potentially anti-tumor in others. Individuals with active cancer or a history of cancer should not take any NAD+ supplementation without oncology guidance ^[4].

On supplement quality. Products vary widely in purity and actual content; third-party testing is not guaranteed.

On human clinical translation. Much of the strongest anti-aging data — lifespan extension, reversal of age-associated decline — comes from rodents, and may not extrapolate to humans. The 2025 Nature Metabolism review's frank conclusion about limited human efficacy should be the reference point, not the rodent data ^[1].

This site does not compile community anecdote reports for NAD+, as its schema-org type (DietarySupplement) and widespread retail market mean self-report data are too context-dependent to summarize responsibly. The cautions above are drawn from the cited peer-reviewed literature.

Where it fits in cellular-energy research

NAD+ is the lead molecule on this desk for a reason: it is the common thread that runs through both mitochondrial energy metabolism and the enzymatic regulation of aging. SIRT1, the sirtuin most studied in aging contexts, requires NAD+ to work; so does the DNA-repair enzyme PARP1; and CD38, whose rise with age depletes the NAD+ pool, is increasingly targeted as an upstream intervention point ^[4][6]. Understanding NAD+ biology is essentially prerequisite to understanding why MOTS-c is interesting — the two are connected through AMPK, which responds to the same energetic signals that NAD+ metabolism reflects.

Read alongside MOTS-c, the mitochondria-derived peptide that activates AMPK via a distinct but complementary route, and compare both on the comparison page.